Aadi Bioscience, Inc.–A Clinical-Stage Biopharmaceutical Company

Aadi industries are focusing on the treating the diseases i.e. drown by the mTOR activation. It is clinical stage biopharmaceutical company led by Dr. Neil Desai, the inventor of ABRAXANE, ABI – 009 and NAB technology Stage. The Company uses the capital to bring the clinical program for the ABI-009 and its targeted the albumin-bound mTOR inhibitor.

  • About ABI – 009 and Aadi –

Aadi leads product i.e. ABI – 009, nanoparticle albumin-bound mTOR inhibitor that based on the rapamycin or sirolimus, also called as nab-rapamycin. Audi aims to develop the full potential of albumin-boundmTOR inhibitor in the diseases that all are driven by the mTOR activation and the mTOR inhibitors are not completed the effectively exploited because of the problem of the effective drug delivery, the effective target to diseases site and safety.

Over in the phase one study, ABI – 009 was well tolerated at the intravenous does scientifically greater than the mTOR inhibitors and pharmacokinetic profiles, with the AUC and high climax are very apart from the approved mTOR inhibitor. While in animals, ABI – 009 has higher antitumor efficacy than the oral mTOR inhibitor at the same dose. As equal to the ABRAXANE, the albumin-found rapamycin is well expected for having greater penetration because of the mechanism of the albumin uptake in tumor and at the other sites with the tissue inflammation or remodeling. Also, ABI – 009 was licensed to the Aadi in the year 2014 by the Celgene Corporation.

Also, AADI Biosciences presently enroll the registration to the advanced Perivascular Epithelioid Cell Tumor or PEComa, an extremely rare form of the sarcoma. Aadi has received the agreement from the FDA on the design of the phase second registration study for the treatment of the advanced PEComa with the ABI – 009.

Are you eligible for the My PEComa or PEC-001 clinically research study -?

  • Older than the age of 18
  • If cancer is being treated but has gotten worse.
  • Are you able to move and capable of the non-strenuous physical activity?
  • Have your doctor told you, about the advanced malignant PEComa?

This study includes the safety and the potential benefit of using investigating medication for treating your diseases. For filling form visit to, AADIBIO webpage. Everyone in the study would receive the same investigational medication.

Tags

Leave a Reply

Your email address will not be published.

top